Merck
  • Home
  • Search Results
  • Enzyme replacement for craniofacial skeletal defects and craniosynostosis in murine hypophosphatasia.

Enzyme replacement for craniofacial skeletal defects and craniosynostosis in murine hypophosphatasia.

Bone (2015-05-12)
Jin Liu, Cassie Campbell, Hwa Kyung Nam, Alexandre Caron, Manisha C Yadav, José Luis Millán, Nan E Hatch
ABSTRACT

Hypophosphatasia (HPP) is an inborn-error-of-metabolism disorder characterized by deficient bone and tooth mineralization due to loss-of function mutations in the gene (Alpl) encoding tissue-nonspecific alkaline phosphatase (TNAP). Alpl(-/-) mice exhibit many characteristics seen in infantile HPP including long bone and tooth defects, vitamin B6 responsive seizures and craniosynostosis. Previous reports demonstrated that a mineral-targeted form of TNAP rescues long bone, vertebral and tooth mineralization defects in Alpl(-/-) mice. Here we report that enzyme replacement with mineral-targeted TNAP (asfotase-alfa) also prevents craniosynostosis (the premature fusion of cranial bones) and additional craniofacial skeletal abnormalities in Alpl(-/-) mice. Craniosynostosis, cranial bone volume and density, and craniofacial shape abnormalities were assessed by microscopy, histology, digital caliper measurements and micro CT. We found that craniofacial shape defects, cranial bone mineralization and craniosynostosis were corrected in Alpl(-/-) mice injected daily subcutaneously starting at birth with recombinant enzyme. Analysis of Alpl(-/-) calvarial cells indicates that TNAP deficiency leads to aberrant osteoblastic gene expression and diminished proliferation. Some but not all of these cellular abnormalities were rescued by treatment with inorganic phosphate. These results confirm an essential role for TNAP in craniofacial skeletal development and demonstrate the efficacy of early postnatal mineral-targeted enzyme replacement for preventing craniofacial abnormalities including craniosynostosis in murine infantile HPP.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Sulfobromophthalein disodium salt hydrate, used to study hepatocyte transport functions
Supelco
Hematoxylin
Sigma-Aldrich
Hematoxylin, certified by the Biological Stain Commission
Sigma-Aldrich
Nitrotetrazolium Blue chloride, powder, electrophoresis grade
Sigma-Aldrich
Nitrotetrazolium Blue chloride, ≥90.0% (HPLC)
Sigma-Aldrich
Calcium phosphate tribasic, 34.0-40.0% Ca basis
Sigma-Aldrich
Calcium phosphate tribasic, suitable for plant cell culture, BioReagent, powder
Sigma-Aldrich
Hydroxyapatite, Type I, buffered aqueous suspension
Sigma-Aldrich
Hydroxyapatite, nanopowder, <200 nm particle size (BET), ≥97%, synthetic
Sigma-Aldrich
Hydroxyapatite, reagent grade, powder, synthetic
Sigma-Aldrich
Hydroxyapatite, synthetic, 99.8% trace metals basis (excludes Mg)
Sigma-Aldrich
Hydroxyapatite, puriss., meets analytical specification of Ph. Eur., BP, FCC, E341, ≥90% (calculated on glowed substance)
Sigma-Aldrich
Hydroxyapatite, purum p.a., ≥90% (as Ca3(PO4)2, KT)
Sigma-Aldrich
Hydroxyapatite, nanopowder, <200 nm particle size (BET), contains 5 wt. % silica as dopant, synthetic
Sigma-Aldrich
Hydroxyapatite, nanoparticles, dispersion, 10 wt. % in H2O, <200 nm particle size (BET)